DiaMedica Therapeutics(DMAC) - 2025 Q3 - Quarterly Results

Financial Performance - Net loss for Q3 2025 was $8.6 million, compared to $6.3 million in Q3 2024, and $24.0 million for the nine months ended September 30, 2025, up from $16.5 million for the same period in 2024[10] - Basic and diluted net loss per share for Q3 2025 was $0.17, compared to $0.15 for Q3 2024[16] - Net loss for the nine months ended September 30, 2025, was $24,026,000, compared to a net loss of $16,544,000 for the same period in 2024, reflecting a deterioration of 45.2%[20] Cash and Investments - DiaMedica reported cash and short-term investments of $55.3 million as of September 30, 2025, an increase from $44.1 million as of December 31, 2024, providing a runway into the second half of 2027[10] - Cash and cash equivalents at the end of the period were $3,326,000, a decrease from $4,134,000 at the end of September 2024[20] - Proceeds from the sale of common shares amounted to $31,527,000, significantly higher than $11,747,000 in the previous year, showing an increase of 168.5%[20] Expenses - Research and Development (R&D) expenses for Q3 2025 were $6.4 million, up from $5.0 million in Q3 2024, and $17.9 million for the nine months ended September 30, 2025, compared to $12.6 million for the same period in 2024[10] - General and Administrative (G&A) expenses increased to $2.6 million for Q3 2025 from $1.9 million in Q3 2024, and $7.3 million for the nine months ended September 30, 2025, compared to $5.7 million for the same period in 2024[10] - Cash flows from operating activities resulted in a net cash outflow of $21,297,000 for the nine months ended September 30, 2025, compared to an outflow of $15,642,000 in 2024[20] Assets and Liabilities - Total assets increased to $57,047,000 as of September 30, 2025, up from $46,345,000 on December 31, 2024, representing a growth of 23.4%[18] - Current assets rose to $56,223,000, compared to $44,610,000 at the end of 2024, marking an increase of 26.2%[18] - Total current liabilities decreased slightly to $5,268,000 from $5,390,000, a reduction of 2.3%[18] - The total non-current liabilities decreased to $157,000 from $237,000, indicating a reduction of 33.8%[18] Shareholder Equity - Shareholders' equity increased to $51,622,000 as of September 30, 2025, up from $40,718,000 at the end of 2024, indicating a growth of 26.9%[18] - The company reported a significant increase in paid-in capital to $215,600,000 from $180,697,000, reflecting a rise of 19.3%[18] Clinical Trials and Development - Enrollment in the ReMEDy2 Phase 2/3 trial for acute ischemic stroke is nearing 50% of the target of 200 patients for the interim analysis expected in the second half of 2026[5] - The completion of cohort 10 in the Preeclampsia Phase 2 IST trial has been achieved, with an expansion cohort now enrolling up to 12 additional participants[6] - The company anticipates screening for participants in the fetal growth restriction cohort to begin in the coming weeks[7] - A pre-IND meeting with the FDA was held to discuss plans for the initiation of a U.S. Phase 2 DM199 study in preeclampsia[5]